Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

Yael L. Maxwell

October 24, 2022

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

News Daily News

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Michael O'Riordan

August 08, 2022

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

L.A. McKeown

June 23, 2022

News Conference News EAS 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

Michael O'Riordan

May 27, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Daily News

SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement

L.A. McKeown

April 27, 2022

News Daily News

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Michael O'Riordan

March 15, 2022

News Daily News

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Michael O'Riordan

February 14, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

Advertisement

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Good News and Bad for High-Intensity Statin Use in ASCVD

SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content